Bio-Rad Laboratories, Inc.
BIO · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $653 | $652 | $585 | $667 |
| % Growth | 0.2% | 11.3% | -12.3% | – |
| Cost of Goods Sold | $310 | $306 | $279 | $326 |
| Gross Profit | $343 | $345 | $306 | $342 |
| % Margin | 52.6% | 53% | 52.3% | 51.2% |
| R&D Expenses | $71 | $61 | $74 | $80 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $207 | $208 | $209 | $204 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $278 | $268 | $282 | $284 |
| Operating Income | $65 | $77 | $24 | $58 |
| % Margin | 10% | 11.8% | 4% | 8.7% |
| Other Income/Exp. Net | -$496 | $337 | $60 | -$967 |
| Pre-Tax Income | -$431 | $414 | $83 | -$909 |
| Tax Expense | $89 | $96 | $19 | -$193 |
| Net Income | -$342 | $318 | $64 | -$716 |
| % Margin | -52.4% | 48.8% | 10.9% | -107.2% |
| EPS | -12.7 | 11.67 | 2.29 | -25.57 |
| % Growth | -208.8% | 409.6% | 109% | – |
| EPS Diluted | -12.7 | 11.67 | 2.29 | -25.57 |
| Weighted Avg Shares Out | 27 | 27 | 28 | 28 |
| Weighted Avg Shares Out Dil | 27 | 27 | 28 | 28 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $15 | $36 | $16 |
| Interest Expense | $12 | $13 | $12 | $12 |
| Depreciation & Amortization | $34 | $51 | $38 | $49 |
| EBITDA | -$385 | $477 | $134 | -$847 |
| % Margin | -58.9% | 73.2% | 22.8% | -127% |